EGFR and non-small cell lung carcinoma: Approximately 37.5%–51.4% of Chinese patients with advanced NSCLC have been found to have somatic activating mutations in EGFR. 1, 2, 3Patients with NSCLC who have somatic mutations of the EGFR gene have been found to benefit from EGFR‐TKIs including gefitinib, erlotinib, afatinib, dacomitinib, osimertinib and so on.